General form of registration statement for all companies including face-amount certificate companies

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.24.3
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]            
Total net revenue $ 2,350,386 $ 298,484 $ 7,154,429 $ 319,143 $ 2,532,499 $ 4,803
Health Care, Patient Service [Member]            
Product Information [Line Items]            
Total net revenue     6,259,806 [1] 248,654 [1] 2,199,558 [2] [2]
Histology Service Fees [Member]            
Product Information [Line Items]            
Total net revenue     811,914 31,854    
Health Care, Other [Member]            
Product Information [Line Items]            
Total net revenue     50,136 2,393 19,324
Department of Defense Observational Studies [Member]            
Product Information [Line Items]            
Total net revenue     8,654 14,250    
Other Revenues [Member]            
Product Information [Line Items]            
Total net revenue     $ 23,919 [3] $ 21,992 [3] 21,515 [4] 4,803 [4]
Histology Fees [Member]            
Product Information [Line Items]            
Total net revenue         272,660
Department Of Defense Observational Studiesr [Member]            
Product Information [Line Items]            
Total net revenue         $ 19,442
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $332,000 and $24,000 for the nine months ended September 30, 2024 and 2023.
[2] Patient services fees includes direct billing for CyPath® Lung diagnostic test.
[3] Other revenues include pre-acquisition CyPath® Lung royalty income and laboratory services.
[4] Other revenues include pre-acquisition CyPath® Lung royalty income and laboratory services.